Treatment of Early Onset Multiple Sclerosis with Suboptimal Dose of Interferon Beta-1a

Abstract

Background: Patients with early onset multiple sclerosis may develop disability at a younger age than adults. There are several reports about safety of beta interferons in childhood and juvenile MS with different doses. Objectives: To determine safety and efficacy of substandard dose of intramuscular interferon beta-1a in a prospective randomized trial in patients with multiple sclerosis under the age of 16. Methods: Sixteen patients were divided into two groups randomly. The first group was treated with intramuscular interferon beta-1a 15 micrograms once a week and the second group received no disease-modifying therapy. Results: The patients were followed for four years. There was no significant side effect and none of the treated patients discontinued the drug. There were significant differences between two groups regarding relapse rates (p = 0.04), disability progression (p = 0.01), and new T2 lesions (p = 0.006). Conclusion: Treatment with interferon beta-1a is well tolerated for a long period of time and may be effective in substandard doses in early onset multiple sclerosis.

Key words

Early onset multiple sclerosis - beta interferon - MS treatment

References

• 1 Adams A B, Tyor W R, Holden K R. Interferon beta-1b and childhood multiple sclerosis.  Pediatr Neurol. 1999;  2 481-483
• 2 Ghezzi A. Clinical characteristics of multiple sclerosis with early onset.  Neurol Sci. 2004;  24 S336-339
• 3 Ghezzi A. Immunomodulatory Treatment of Early onset MS (ITEMS) Group . Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study.  Neurol Sci. 2005;  26 s183-186
• 4 Koch-Henriksen N, Sorensen P S, Christensen T, Frederiksen J, Ravnborg M, Jensen K. et al . A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.  Neurology. 2006;  66 1056-1060
• 5 Kurtzke J F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).  Neurology. 1983;  33 1444-1452
• 6 Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O. et al . Interferon-beta treatment in patients with childhood-onset multiple sclerosis.  J Pediatr. 2001;  139 443-446
• 7 Poser C M, Paty D W, Scheinberg L, McDonald W I, Davis F A, Ebers G C. et al . New diagnosis criteria for multiple sclerosis: guidelines for research protocols.  Ann Neurol. 1983;  13 227-231
• 8 Ozakbas S, Idiman E, Baklan B, Yulug B. Childhood and juvenile onset multiple sclerosis: Clinical and paraclinical features.  Brain & Development. 2003;  25 233-236
• 9 Simone I L, Carrara D, Tortorella C, Liguori M, Lepore V, Pellegrini F. et al . Course and prognosis in early-onset MS. Comparison with adult-onset forms.  Neurology. 2002;  59 1922-1928
• 10 Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi L ME. Multiple sclerosis in children under 10 years of age.  Neurol Sci. 2004;  25 S326-335
• 11 Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J. et al . Interferon beta-1a in children with multiple sclerosis is well tolerated.  Neuropediatrics. 2001;  32 211-213